- Created on the 20 March, 2017.
Interferon-alpha (IFN-alpha) is a type I interferon which belongs to a large group of proteins which are known as cytokines. There have been more than twenty distinct IFNs that have been identified in humans and animals. There are three main classes of interferons that have been identified alpha, beta and gamma. Their main function is modulate the response of the immune system to cancer, viruses, bacteria, and other foreign substances that invade the body. They do not directly kill cancerous or viral cells but instead they are able to boost the immune system response in order to reduce the growth of cancer cells through regulating the action of several genes that can affect growth.
Interferon are typically divided between three classes Type I, II and III IFNs. IFN-alpha is predominately produced by lymphoblastic cells, macrophages or monocytes and fibroblasts, however many other virus activated cells also have the ability to produce this cytokine. IFNα is able to bind to specific transmembrane interferon receptors, this can lead to the activation of various signalling pathways such as MAP kinase, JAK-STAT, IRS signalling and Crk-pathway. In the last few decades IFN-alpha has emerged as a major player for the therapeutic modality for several malignant and non-malignant diseases, by far the most common indication for IFNα treatment is hepatitis C virus (HCV) infection. IFN-alpha displays anti-parasitic, anti-proliferative and antiviral properties and increased levels of it have suggested a recent or ongoing viral or parasitic infection.
Human IFN-alpha ELISA kit is designed for analysing in vitro quantitative concentrations of interferon-alpha (IFN-alpha, IFN-α) in human plasma, serum and cell culture supernatant. This assay has a minimum detection limit of < 0.6 ng/ml.
The minimum detection sensitivity level of interferon-alpha (IFN-alpha or IFN-α) using this human IFN-alpha ELISA kit was 0.6 ng/ml. The dynamic assay range for this kit is 15.6 – 1,000 ng/ml.
- Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. (2015) 98 (2): 185-94. Review. Gonzales-van Horn S.R. and Farrar J.D.
- Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. (2010) 43 (3): 204-9. Review. Rizza P., et al.
- IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol. (2013) 168 (5): 1048-58. Review. Gibbert K., et al.
- New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother. (2005) 54 (1): 1-10. Review. Tagliaferri P., et al.
- New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. Cancer Sci. (2003) 94 (5): 405-11. Review. Takaoka A. and Taniguchi T.
- Therapeutic alpha-interferons protein: structure, production, and biosimilar. Prep Biochem Biotechnol. (2015) 45 (2): 109-27. Review. El-Baky N.A. and Redwan E.M.
- Full Name: Interferon-Alpha (IFN-Alpha) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma, Cell Culture Supernatant
- Sensitivity: < 0.6 ng/ml